R&D | January 23, 2026
Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies
The partnership initially will focus on cardiovascular and kidney diseases
The partnership initially will focus on cardiovascular and kidney diseases
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
MRI is particularly valuable in pediatric care due to its non-invasive nature
Subscribe To Our Newsletter & Stay Updated
